SMN2 and proximal spinal muscular atrophy: Different therapies targeting these modifiers have been developed for SMA patients, such as an antisense oligonucleotide (ASO) approach targeting an SMN2 intronic splicing silencer, thereby facilitating the generation of SMN2-FL transcripts (1).